

The Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing

<https://neurodegenerationresearch.eu/survey/the-australian-imaging-biomarkers-lifestyle-flagship-study-of-ageing/>

Title of study

The Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing

Acronym for cohort

AiBL

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

David

Name of Principal Investigator - Last name

Ames

Address of institution -Institution

The Florey

Address of institution - Street address

30 Royal Parade

Address of institution - City

Parkville

Address of institution - Postcode

3010

Country

Australia

Website

<https://aibl.csiro.au>

Contact email

Funding source

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias|Neurodegenerative disease in general

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

Longitudinal observational study of the natural history of AD

Q2b. What distinguishes this case-control study from other studies?

Emphasis on molecular imaging of A β and Tau

Q3a. i) Number of publications that involve use of your cohort to date

189

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

Lim YY. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. 2016|Gupta VB. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging Biomarkers and Lifestyle Study of ageing. 2016|Lim YY. Performance on the Cogstate Brief Battery is related to amyloid levels and hippocampal volume in very mild dementia. 2016

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

Refer to AiBL website: <https://aibl.csiro.au>

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

60

Q4a. Study criteria: what is the age range of participants at recruitment? To:

90

Q4b. Study criteria: what are the inclusion criteria?

See: Ellis KA et al. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Int Rev Psychiatry. 2013; 25:699-710

Q4c. Study criteria: what are the exclusion criteria?

See: Ellis KA et al. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Int Rev Psychiatry. 2013; 25:699-710

Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

1,001-5,000

Q5b. What is the expected number of control participants?

501-1,000

Q6a. Please describe what measures are used to characterise participants

See: Ellis KA et al. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Int Rev Psychiatry. 2013; 25:699-710

Q6b. Are there additional measures for participants with the clinical disorder?

No

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If YES please specify

Q7. What is the study design?

Prospective cohort|Genome wide association study (GWAS)|Age|Sex

Q8. Are your cases matched by

Co-morbidities|Cognitive function|Physical ability

Q9a. Does your study includes a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe

Q10a. Is data collection for this study

Data collection ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - funding applied for

Q11. Are data collected

Only through the study

Q12. Is there a system in place to enable re-contact with patients for future studies?

Yes (participants have given permission to be re-contacted via the PIs)

Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available

Q13a. Please give information on data stored in a database (2)

Data summarised in database

% Available

Q13a. Please give information on data stored in a database (3)

Database on spreadsheet (e.g. excel)

% Available

Q13a. Please give information on data stored in a database (4)

No

% Available

Q13a. Please give information on data stored in a database (5)

No

% Available

Please specify language used

% Available

Q13b. Please give information on how data is held as individual records

Data is web-based

% Available

Q14a. Are data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource|Access Committee mechanism|Other access mechanism|International access|Access to industry|Access for pilot studies permitted|Applicant needs to provide separate external ethics approval|Resource has own ethics approval so usually no need for separate external ethics approval

Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below

Living donors: blood|Living donors: blood derivatives|Living donors: cerebro-spinal fluid|Living donors: cerebro-spinal fluid|Post-mortem donors: spinal cord

Q16b. ii) In what form are tissues/samples/DNA supplied?

Primary samples: Supplied fresh|Primary Samples: Stabilised samples (frozen or fixed)|Secondary samples:(derivatives of primary samples)|Secondary samples: plasma|Secondary samples: DNA|Secondary samples: RNA|Secondary samples: protein extracts

Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Types:

Case Control Studies

Member States:

Australia

Diseases:

Alzheimer's disease & other dementias, Neurodegenerative disease in general

Years:

2016

Database Categories:

N/A

Database Tags:

N/A